医学
硬皮病(真菌)
疾病
亚临床感染
免疫系统
多发性硬化
系统性硬皮病
免疫学
干细胞
移植
自身免疫性疾病
全身性疾病
治疗方法
生物信息学
个性化医疗
免疫失调
造血
再生医学
精密医学
重症监护医学
自身免疫
神经科学
器官移植
器官系统
结缔组织病
作者
C Rolo Santos,Yannick Allanore,Marco Matucci‐Cerinic
标识
DOI:10.1097/bor.0000000000001204
摘要
PURPOSE OF REVIEW: To summarize recent advances in systemic sclerosis (SSc) highlighted at the 2026 World Scleroderma Congress, focusing on early disease, immunovascular mechanisms, and emerging therapeutic strategies. RECENT FINDINGS: Recent data support a paradigm shift in SSc, demonstrating that disease onset occurs during a very early phase (VEDOSS) characterized by early immune activation and microvascular dysfunction. Type I interferon-driven pathways are increasingly implicated in vascular and myocardial involvement, reinforcing the concept of a shared immunovascular axis across organ systems. Advances in multimodal imaging and circulating biomarkers enable detection of subclinical organ disease, while multi-omic and data-driven approaches are redefining disease subsets beyond traditional classifications. In parallel, novel therapeutic strategies - including targeted immune modulation, autologous haematopoietic stem cell transplantation (AHSCT), and emerging CAR-T approaches - are driving a transition toward earlier, mechanism-based intervention. SUMMARY: Systemic sclerosis is increasingly understood as a dynamic continuum of autoimmune/inflammatory and fibrotic mechanisms that can be identified through imaging, biohumoral, and functional insights, thus enabling a very early/early diagnosis, a risk stratification, and a precision-based therapeutic approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI